134 related articles for article (PubMed ID: 10334527)
1. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Valero V; Buzdar AU; Theriault RL; Azarnia N; Fonseca GA; Willey J; Ewer M; Walters RS; Mackay B; Podoloff D; Booser D; Lee LW; Hortobagyi GN
J Clin Oncol; 1999 May; 17(5):1425-34. PubMed ID: 10334527
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
[TBL] [Abstract][Full Text] [Related]
3. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
5. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
8. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Khayat D; Chollet P; Antoine EC; Monfardini S; Ambrosini G; Benhammouda A; Mazen MF; Sorio R; Borg-Olivier O; Riva A; Ramazeilles C; Azli N
J Clin Oncol; 2001 Jul; 19(14):3367-75. PubMed ID: 11454884
[TBL] [Abstract][Full Text] [Related]
11. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
13. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study.
Giotta F; Lorusso V; Maiello E; Filippelli G; Valerio MR; Caruso M; Verderame F; Latorre A; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi66-9. PubMed ID: 17591836
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
